287 related articles for article (PubMed ID: 21489988)
21. Seed sequence-matched controls reveal limitations of small interfering RNA knockdown in functional and structural studies of hepatitis C virus NS5A-MOBKL1B interaction.
Chung HY; Gu M; Buehler E; MacDonald MR; Rice CM
J Virol; 2014 Oct; 88(19):11022-33. PubMed ID: 25031347
[TBL] [Abstract][Full Text] [Related]
22. Molecular and structural characterization of the domain 2 of hepatitis C virus non-structural protein 5A.
Liang Y; Kang CB; Yoon HS
Mol Cells; 2006 Aug; 22(1):13-20. PubMed ID: 16951545
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.
Fernandes F; Ansari IU; Striker R
PLoS One; 2010 Mar; 5(3):e9815. PubMed ID: 20352119
[TBL] [Abstract][Full Text] [Related]
24. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.
Chatterji U; Bobardt MD; Lim P; Gallay PA
J Gen Virol; 2010 May; 91(Pt 5):1189-93. PubMed ID: 20107018
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
Nevers Q; Ruiz I; Ahnou N; Donati F; Brillet R; Softic L; Chazal M; Jouvenet N; Fourati S; Baudesson C; Bruscella P; Gelin M; Guichou JF; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760125
[TBL] [Abstract][Full Text] [Related]
26. The domain 2 of the HCV NS5A protein is intrinsically unstructured.
Hanoulle X; Badillo A; Verdegem D; Penin F; Lippens G
Protein Pept Lett; 2010 Aug; 17(8):1012-8. PubMed ID: 20450484
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
Madan V; Paul D; Lohmann V; Bartenschlager R
Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
[TBL] [Abstract][Full Text] [Related]
28. Correlation between NS5A dimerization and hepatitis C virus replication.
Lim PJ; Chatterji U; Cordek D; Sharma SD; Garcia-Rivera JA; Cameron CE; Lin K; Targett-Adams P; Gallay PA
J Biol Chem; 2012 Aug; 287(36):30861-73. PubMed ID: 22801423
[TBL] [Abstract][Full Text] [Related]
29. Structural and molecular basis of interaction of HCV non-structural protein 5A with human casein kinase 1α and PKR.
Sudha G; Yamunadevi S; Tyagi N; Das S; Srinivasan N
BMC Struct Biol; 2012 Nov; 12():28. PubMed ID: 23148689
[TBL] [Abstract][Full Text] [Related]
30. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors.
Nag A; Robotham JM; Tang H
J Virol; 2012 Dec; 86(23):12616-24. PubMed ID: 22973029
[TBL] [Abstract][Full Text] [Related]
31. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex.
Liu Z; Yang F; Robotham JM; Tang H
J Virol; 2009 Jul; 83(13):6554-65. PubMed ID: 19386705
[TBL] [Abstract][Full Text] [Related]
32. HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A.
Shanmugam S; Nichols AK; Saravanabalaji D; Welsch C; Yi M
PLoS Pathog; 2018 Jul; 14(7):e1007177. PubMed ID: 30036383
[TBL] [Abstract][Full Text] [Related]
33. Intrinsically unstructured domain 3 of hepatitis C Virus NS5A forms a "fuzzy complex" with VAPB-MSP domain which carries ALS-causing mutations.
Gupta G; Qin H; Song J
PLoS One; 2012; 7(6):e39261. PubMed ID: 22720086
[TBL] [Abstract][Full Text] [Related]
34. The Casein Kinase 2-Dependent Phosphorylation of NS5A Domain 3 from Hepatitis C Virus Followed by Time-Resolved NMR Spectroscopy.
Secci E; Luchinat E; Banci L
Chembiochem; 2016 Feb; 17(4):328-33. PubMed ID: 26684216
[TBL] [Abstract][Full Text] [Related]
35. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
[TBL] [Abstract][Full Text] [Related]
36. NS5A Domain 1 and Polyprotein Cleavage Kinetics Are Critical for Induction of Double-Membrane Vesicles Associated with Hepatitis C Virus Replication.
Romero-Brey I; Berger C; Kallis S; Kolovou A; Paul D; Lohmann V; Bartenschlager R
mBio; 2015 Jul; 6(4):e00759. PubMed ID: 26152585
[TBL] [Abstract][Full Text] [Related]
37. Cyclophilin inhibitors for the treatment of HCV infection.
Fischer G; Gallay P; Hopkins S
Curr Opin Investig Drugs; 2010 Aug; 11(8):911-8. PubMed ID: 20721833
[TBL] [Abstract][Full Text] [Related]
38. The isomerase active site of cyclophilin A is critical for hepatitis C virus replication.
Chatterji U; Bobardt M; Selvarajah S; Yang F; Tang H; Sakamoto N; Vuagniaux G; Parkinson T; Gallay P
J Biol Chem; 2009 Jun; 284(25):16998-17005. PubMed ID: 19380579
[TBL] [Abstract][Full Text] [Related]
39. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication.
Lindenbach BD; Prágai BM; Montserret R; Beran RK; Pyle AM; Penin F; Rice CM
J Virol; 2007 Sep; 81(17):8905-18. PubMed ID: 17581983
[TBL] [Abstract][Full Text] [Related]
40. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics.
Kaul A; Stauffer S; Berger C; Pertel T; Schmitt J; Kallis S; Zayas M; Lohmann V; Luban J; Bartenschlager R
PLoS Pathog; 2009 Aug; 5(8):e1000546. PubMed ID: 19680534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
